Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric cancer in real-world patients: Updated analysis.

被引：0
|
作者：
Shimozaki, Keitaro
Fukuda, Koshiro
Ooki, Akira
Nakayama, Izuma
Yoshino, Koichiro
Udagawa, Shohei
Fukuoka, Shota
Osumi, Hiroki
Ogura, Mariko
Wakatsuki, Takeru
Takahari, Daisuke
Shinozaki, Eiji
Chin, Keisho
Yamaguchi, Kensei
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol Chemotherapy, Koto Ku, Koto, Japan
[2] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Tokyo, Japan
[3] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[4] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Advanved Med Dev, Tokyo, Japan
[5] Canc Inst Hosp, Japanese Fdn Canc Res, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.341
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：341 / 341
页数：1
相关论文
共 50 条
  • [1] The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer
    Liu, Yu-Yin
    Tsai, Ming-Yen
    Liu, Ting-Ting
    Liu, Yueh-Wei
    Lin, Yu-Hung
    Yeh, Cheng-Hsi
    Lin, Yu-Cheng
    Chen, Yen-Hao
    BMC CANCER, 2024, 24 (01)
  • [2] First-line (1L) anti-PD-1 plus chemotherapy in HER2-negative advanced gastric cancer: Real-world evidence from a single Korean center
    Shim, Joosung Gabriel
    Jung, Minkyu
    Kim, Hyunwook
    Kim, Kyoo Hyun
    Kim, Taeho
    Kim, Youhyun
    Shim, Hyo Sup
    Kim, Hyunki
    Kim, Hyo Song
    Lee, Choong-kun
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 83 - 83
  • [3] A RETROSPECTIVE ANALYSIS OF FIRST-LINE TREATMENT IN HER2-POSITIVE AND HER2-NEGATIVE ADVANCED GASTRIC CANCER
    Onodera, K.
    Kawakami, K.
    Yukisawa, S.
    Warita, E.
    Yamanaka, Y.
    ANNALS OF ONCOLOGY, 2013, 24 : 68 - 68
  • [4] Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study
    Kutlu, Yasin
    Dae, Shute Ailia
    Yilmaz, Feride
    Erdem, Dilek
    Sendur, Mehmet Ali Nahit
    Akbas, Sinem
    Senocak Tasci, Elif
    Bas, Onur
    Dane, Faysal
    Sakin, Abdullah
    Kaya, Ali Osman
    Aykan, Musa Baris
    Ergun, Yakup
    Biter, Sedat
    Disel, Umut
    Korkmaz, Mustafa
    Selcukbiricik, Fatih
    Kose, Fatih
    Olmez, Omer Fatih
    Bilici, Ahmet
    Demir, Gokhan
    Yalcin, Suayib
    CANCERS, 2024, 16 (12)
  • [5] Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab
    Kozak, Katarzyna
    Teterycz, Pawel
    Galus, Lukasz
    Mackiewicz, Jacek
    Galwas-Kliber, Katarzyna
    Kaminska-Winciorek, Grazyna
    Brandys, Piotr
    Cybulska-Stopa, Bozena
    Kempa-Kaminska, Natasza
    Zietek, Marcin
    Zubrowska, Justyna
    Dziura, Robert
    Dembinski, Mateusz
    Bereza, Michal
    Czarnecka, Anna Malgorzata
    Rutkowski, Piotr
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair
    Park, Young-Gyu
    Kim, Hyung-Don
    Hyung, Jaewon
    Park, Young Soo
    Ryu, Min-Hee
    GASTRIC CANCER, 2024, 27 (04) : 840 - 849
  • [7] A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group
    Nishina, Tomohiro
    Boku, Narikazu
    Kurokawa, Yukinori
    Sasaki, Keita
    Machida, Ryunosuke
    Yoshikawa, Takaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (10) : 1100 - 1106
  • [8] Real-world effectiveness and safety of first-line bevacizumab (BEV) plus paclitaxel (PAC) in > 2000 patients (pts) with HER2-negative metastatic breast cancer (mBC)
    Mueller, V.
    Dank, M.
    de Ducla, S.
    Mitchell, L.
    Schneeweiss, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Nivolumab plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastroesophageal junction cancer-regional differences in efficacy
    Mehta, Rutika
    Shah, Manish A.
    ANNALS OF PALLIATIVE MEDICINE, 2022,
  • [10] The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab plus nivolumab vs. nivolumab in a real-world setting
    Billard, Karine
    Mortier, Laurent
    Dereure, Olivier
    Dalac, Sophie
    Montaudie, Henri
    Legoupil, Delphine
    Dutriaux, Caroline
    De Quatrebarbes, Julie
    Maubec, Eve
    Leccia, Marie-Therese
    Granel-Brocard, Florence
    Brunet-Possenti, Florence
    Arnault, Jean-Philippe
    Gaudy-Marqueste, Caroline
    Pages, Cecile
    Saiag, Philippe
    L'Orphelin, Jean-Matthieu
    Zehou, Ouidad
    Lesimple, Thierry
    Allayous, Clara
    Porcher, Raphael
    Oriano, Bastien
    Dalle, Stephane
    Lebbe, Celeste
    BRITISH JOURNAL OF DERMATOLOGY, 2025,
12345